Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
2008 3
2009 5
2010 3
2011 5
2012 6
2013 7
2014 11
2015 4
2016 7
2017 8
2018 4
2019 4
2020 4
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

64 results
Results by year
Filters applied: . Clear all
Page 1
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, Peters S, Ponce S, Fernández C, Alfaro V, Gómez J, Kahatt C, Zeaiter A, Zaman K, Boni V, Arrondeau J, Martínez M, Delord JP, Awada A, Kristeleit R, Olmedo ME, Wannesson L, Valdivia J, Rubio MJ, Anton A, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D'Arcangelo M, Santoro A, Villalobos VM, Sands J, Paz-Ares L. Trigo J, et al. Among authors: sarantopoulos j. Lancet Oncol. 2020 May;21(5):645-654. doi: 10.1016/S1470-2045(20)30068-1. Epub 2020 Mar 27. Lancet Oncol. 2020. PMID: 32224306 Clinical Trial.
RANK ligand: effects of inhibition.
George S, Brenner A, Sarantopoulos J, Bukowski RM. George S, et al. Among authors: sarantopoulos j. Curr Oncol Rep. 2010 Mar;12(2):80-6. doi: 10.1007/s11912-010-0088-1. Curr Oncol Rep. 2010. PMID: 20425591 Review.
The Pim kinases: new targets for drug development.
Swords R, Kelly K, Carew J, Nawrocki S, Mahalingam D, Sarantopoulos J, Bearss D, Giles F. Swords R, et al. Among authors: sarantopoulos j. Curr Drug Targets. 2011 Dec;12(14):2059-66. doi: 10.2174/138945011798829447. Curr Drug Targets. 2011. PMID: 21777193 Review.
The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours.
Pooler DB, Ness DB, Sarantopoulos J, Squittieri N, Ravichandran S, Britten CD, Amaravadi RK, Vaishampayan U, LoRusso P, Shapiro GI, Olszanski AJ, Perez R, Gutierrez M, O'Rourke MA, Chung V, Lee JJ, Lewis LD. Pooler DB, et al. Among authors: sarantopoulos j. Br J Clin Pharmacol. 2021 Mar;87(3):1291-1302. doi: 10.1111/bcp.14508. Epub 2020 Aug 20. Br J Clin Pharmacol. 2021. PMID: 32736411 Clinical Trial.
Academic Cancer Center Phase I Program Development.
Frankel AE, Flaherty KT, Weiner GJ, Chen R, Azad NS, Pishvaian MJ, Thompson JA, Taylor MH, Mahadevan D, Lockhart AC, Vaishampayan UN, Berlin JD, Smith DC, Sarantopoulos J, Riese M, Saleh MN, Ahn C, Frenkel EP. Frankel AE, et al. Among authors: sarantopoulos j. Oncologist. 2017 Apr;22(4):369-374. doi: 10.1634/theoncologist.2016-0409. Epub 2017 Mar 17. Oncologist. 2017. PMID: 28314841 Free PMC article.
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.
Subbiah V, Paz-Ares L, Besse B, Moreno V, Peters S, Sala MA, López-Vilariño JA, Fernández C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Zaman K, López R, Ponce S, Boni V, Arrondeau J, Delord JP, Martínez M, Wannesson L, Antón A, Valdivia J, Awada A, Kristeleit R, Olmedo ME, Rubio MJ, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D' Arcangelo M, Santoro A, Villalobos VM, Sands J, Trigo J. Subbiah V, et al. Among authors: sarantopoulos j. Lung Cancer. 2020 Dec;150:90-96. doi: 10.1016/j.lungcan.2020.10.003. Epub 2020 Oct 10. Lung Cancer. 2020. PMID: 33096421 Free article. Clinical Trial.
Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours.
Mahalingam D, Patel MR, Sachdev JC, Hart LL, Halama N, Ramanathan RK, Sarantopoulos J, Völkel D, Youssef A, de Jong FA, Tsimberidou AM. Mahalingam D, et al. Among authors: sarantopoulos j. Br J Clin Pharmacol. 2020 Sep;86(9):1836-1848. doi: 10.1111/bcp.14289. Epub 2020 Apr 12. Br J Clin Pharmacol. 2020. PMID: 32207164 Free PMC article. Clinical Trial.
Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity.
Mahalingam D, Wang JS, Hamilton EP, Sarantopoulos J, Nemunaitis J, Weems G, Carter L, Hu X, Schreeder M, Wilkins HJ. Mahalingam D, et al. Among authors: sarantopoulos j. Clin Cancer Res. 2019 Jun 15;25(12):3508-3516. doi: 10.1158/1078-0432.CCR-18-3185. Epub 2019 Feb 28. Clin Cancer Res. 2019. PMID: 30819679 Free article. Clinical Trial.
64 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page